Show simple item record

dc.contributor.authorOkoboi, Stephen
dc.contributor.authorEkwaru, Paul John
dc.contributor.authorCampbell, James D.
dc.contributor.authorEgessa, Aggrey
dc.contributor.authorKing, Racheal
dc.contributor.authorBakanda, Celestin
dc.contributor.authorMuramuzi, Emmy
dc.contributor.authorKaharuza, Frank
dc.contributor.authorMalamba, Samuel
dc.contributor.authorMoore, David M.
dc.date.accessioned2022-02-04T11:35:24Z
dc.date.available2022-02-04T11:35:24Z
dc.date.issued2015
dc.identifier.citationOkoboi, S., Ekwaru, P. J., Campbell, J. D., Egessa, A., King, R., Bakanda, C., ... & Moore, D. M. (2015). No differences in clinical outcomes with the addition of viral load testing to CD4 cell count monitoring among HIV infected participants receiving ART in rural Uganda: Long-term results from the Home Based AIDS Care Project. BMC Public Health, 16(1), 1-8. DOI 10.1186/s12889-016-2781-yen_US
dc.identifier.other10.1186/s12889-016-2781-y
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/1882
dc.description.abstractWe compared clinical outcomes among HIV-infected participants receiving ART who were randomized to viral load (VL) and CD4 cell count monitoring in comparison to CD4 cell count monitoring alone in Tororo, Uganda. Methods: Beginning in May 2003, participants with CD4 cell counts <250 cells/μL or WHO stage 3 or 4 disease were randomized to clinical monitoring alone, clinical monitoring plus quarterly CD4 cell counts (CD4-only); or clinical monitoring, quarterly CD4 cell counts and quarterly VL testing (CD4-VL). In 2007, individuals in clinical monitoring arm were re-randomized to the other two arms and all participants were followed until March 31, 2009. We used Cox Proportional Hazard models to determine if study arm was independently associated with the development of opportunistic infections (OIs) or death. Results: We randomized 1211 participants to the three original study arms and 331 surviving participants in the clinical monitoring arm were re-randomized to the CD4-VL and CD4 only arms. At enrolment the median age was 38 years and the median CD4 cell count was 134 cells/μL. Over a median of 5.2 years of follow-up, 37 deaths and 35 new OIs occurred in the VL-CD4 arm patients, 39 deaths and 42 new OIs occurred in CD4-only patients. We did not observe an association between monitoring arm and new OIs or death (AHR =1.19 for CD4-only vs. CD4-VL; 95 % CI 0.82–1.73). Conclusion: We found no differences in clinical outcomes associated with the addition of quarterly VL monitoring to quarterly CD4 cell count monitoring.en_US
dc.language.isoenen_US
dc.publisherBMC Public Healthen_US
dc.subjectAntiretroviral therapyen_US
dc.subjectVirologic failureen_US
dc.subjectMorbidityen_US
dc.subjectMortalityen_US
dc.subjectSub-Saharan Africaen_US
dc.subjectUgandaen_US
dc.titleNo differences in clinical outcomes with the addition of viral load testing to CD4 cell count monitoring among HIV infected participants receiving ART in rural Uganda: Long-term results from the Home Based AIDS Care Projecten_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record